Coenzyme Q10 serum levels in Huntington's disease.
Mitochondrial dysfunction contributes to the neurodegenerative process in Huntington's disease (HD). Coenzyme Q10 (CoQ10) enhances mitochondrial complex I activity and may therefore provide a therapeutic benefit in HD. We compared serum CoQ10 levels of previously untreated-and treated HD patients with those of healthy controls. CoQ10 did not significantly (ANCOVA F(dF 2, dF 55) = 2.57; p=0.086) differ between all three groups. However, the post hoc analysis showed no significant (p = 0.4) difference between treated HD patients ([CoQ10]: 88.12 [mean]+/-24.44 [SD], [range] 48.75-146.32 [pg/million platelets]) and controls (93.71+/-20.72, 65.31-157.94), however previously untreated HD patients (70.10+/-21.12, 38.67-106.14) had marked (p = 0.051) lower CoQ10 results than treated HD patients and controls (p = 0.017). Our results support that CoQ10 supplementation in HD patients may reduce impaired mitochondrial function in HD.
Andrich
J
J
Department of Neurology, St Josef Hospital, Ruhr University, Bochum, Germany.
Saft
C
C
Gerlach
M
M
Schneider
B
B
Arz
A
A
Kuhn
W
W
Müller
Th
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D003067:Coenzymes; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000097:blood / Q000188:drug therapy / Q000201:enzymology*; D008297:Male; D008875:Middle Aged; D018709:Statistics, Nonparametric; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000097:blood* / Q000627:therapeutic use
D003067:Coenzymes; D014451:Ubiquinone; C024989:coenzyme Q10